[Translated article] Real-world persistence with dolutegravir/lamivudine versus bictegravir/emtricitabine/tenofovir-alafenamide among persons with HIV
Farmacia Hospitalaria · 2024
DOI: 10.1016/j.farma.2024.02.016 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Farmacia Hospitalaria, 2024. Verfasst von Lorena Martín-Zaragoza und 6 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Farmacia, Hospital Universitario de Getafe, Getafe, Spain. Electronic address: lmartinz@salud.madrid.org. Hauptthemen laut MEDLINE: HIV Infections, Pyridones, Lamivudine, Piperazines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
OBJETIVES: The main objective was to compare the persistence between dolutegravir/lamivudine (DTG/3TC) and bictegravir/emtricitabine/tenofovir-alafenamide (BIC/FTC/TAF) and to analyze reasons for discontinuation. METHODS: We conducted a retrospective, non-interventional, descriptive, and longitudinal study. All human immunodeficiency virus (HIV) patients over 18 years treated with DTG/3TC or BIC/FTC/TAF in our center were included. Persistence after first year was compared using the χ2 test. Kaplan-Meier survival analysis was performed. RESULTS: Three hundred fifty-eight patients were included. 99.5% versus 90.99% of patients were persistent after the first year for DTG/3TC and BIC/FTC/TAF respectively (p=.001). Persistence with DGT/3TC was 1237 days (IC95% 1216-1258) and persistence with BIC/FTC/TAF was 986 days [(IC95% 950-1021); p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Servicio de Farmacia, Hospital Universitario de Getafe, Getafe, Spain. Electronic address: lmartinz@salud.madrid.org.
- Servicio de Farmacia, Hospital Universitario de Getafe, Getafe, Spain.
- Servicio de Medicina Interna, Hospital Universitario de Getafe, Getafe, Spain.
Zitieren
APA
Martín-Zaragoza, L., Sánchez-Rubio-Ferrández, J., Onteniente-González, A., Gómez-Bermejo, M., Rodríguez-Álvarez, S. J., Monereo-Alonso, A., & Molina-García, T. (2024). [Translated article] Real-world persistence with dolutegravir/lamivudine versus bictegravir/emtricitabine/tenofovir-alafenamide among persons with HIV. Farmacia Hospitalaria. https://doi.org/10.1016/j.farma.2024.02.016
Vancouver
Martín-Zaragoza L, Sánchez-Rubio-Ferrández J, Onteniente-González A, Gómez-Bermejo M, Rodríguez-Álvarez SJ, Monereo-Alonso A, et al. [Translated article] Real-world persistence with dolutegravir/lamivudine versus bictegravir/emtricitabine/tenofovir-alafenamide among persons with HIV. Farmacia Hospitalaria. 2024. doi:10.1016/j.farma.2024.02.016
BibTeX
@article{MartnZaragoza2024,
author = {Martín-Zaragoza, Lorena and Sánchez-Rubio-Ferrández, Javier and Onteniente-González, Alberto and Gómez-Bermejo, Marcos and Rodríguez-Álvarez, Sergio Julio and Monereo-Alonso, Alfonso and Molina-García, Teresa},
title = {[Translated article] Real-world persistence with dolutegravir/lamivudine versus bictegravir/emtricitabine/tenofovir-alafenamide among persons with HIV},
journal = {Farmacia Hospitalaria},
year = {2024},
doi = {10.1016/j.farma.2024.02.016}
}
EUVIMED